Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vobarilizumab + MTX in RA
NCT02309359Phase 2Completed
- Sponsor
- Sanofi
- Start
- Jan 2015
- Primary completion
- Aug 2016
- Modality
- Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 14
01
Overview
A Phase 2 trial of vobarilizumab in rheumatoid arthritis (RA), sponsored by Sanofi. Started Jan 2015; status: completed.
02
Drugs
vobarilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02309359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02309359.